← Back to News
Research

Study Projects Increase in Annual Mantle Cell Lymphoma Diagnoses by 2032

By MCLA Staff ·

Compiled by MCLA Staff. Reviewed by Michael E. Williams, MD, ScM, FACP, University of Virginia.

A new study by researchers from Merck, using data from the National Cancer Institute, projects that annual diagnoses of mantle cell lymphoma (MCL) in the United States will increase over the coming years. By 2032, the number of new MCL diagnoses each year is expected to be about 6% higher than it was in 2023. The study also projects more diagnoses among women and people younger than 65, while the total number of people living with MCL is expected to grow.

Why is this study important to you?

This study provides an early look at how the needs of the MCL community may change in the years ahead as more people are diagnosed with MCL, more people live with the disease, and more patients need treatment throughout their journey. The study also points to changing trends in who is being diagnosed, including growth among younger adults. Because younger patients may live with MCL for many years and need several different treatments over time, these findings reinforce the need for treatments that work longer and preserve quality of life by mitigating therapy-related side effects.

What are the details of the study?

Researchers analyzed National Cancer Institute cancer registry and Medicare data to estimate how MCL may change through 2032. They project about a 6% increase in new MCL diagnoses over the decade, along with more patients needing treatment across all lines of therapy. The study forecasts a 43% increase in new diagnoses among women and a 33% increase among people younger than 65. Importantly, MCL is still expected to occur mainly in older adults.

One important caveat is that these are statistical forecasts based on past data. It is generally true that looking back at past patient data may have statistical limitations compared to looking forward with clinical trial experiments. Furthermore, this study does not explain why diagnoses are expected to increase faster in people younger than 65, nor does it suggest that MCL is becoming mainly a disease of younger adults.

What could this mean for the future of MCL?

These findings highlight the growing need for MCL research, patient support, and better treatments. As more people are diagnosed and live longer with MCL, patients will need ongoing care and additional therapies. Although today’s treatments have improved outcomes, most patients still experience relapse and require multiple lines of treatment. More durable treatment responses will be critical to helping patients live longer and better with MCL, as will ongoing research to achieve deep remissions and potential cure.

Sources

Share this article